capecitabine has been researched along with ma-1 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amellal, N; Argilés, G; Aubel, P; Borg, C; Danielewicz, I; Egorov, A; Falcone, A; Fedyanin, M; Garcia-Alfonso, P; Glynne-Jones, R; Kanehisa, A; Kroening, H; Moiseenko, V; Pfeiffer, P; Punt, CJA; Saunders, MP; Stroyakovskiy, D; Van Cutsem, E; Van de Wouw, AJ; Wasan, H | 1 |
| Aleshin, A; Billings, PR; Ebi, H; Kato, T; Kotani, D; Mishima, S; Mori, M; Nakamura, Y; Oki, E; Rabinowitz, M; Sawada, K; Shirasu, H; Takemasa, I; Taniguchi, H; Yamanaka, T; Yoshino, T; Yukami, H | 1 |
| Chen, Y; Hu, J; Luo, S; Lv, D; Wu, Z; Xie, X; Yang, B; Zhang, S | 1 |
| Amellal, N; André, T; Aubel, P; Campos-Bragagnoli, A; Chmielowska, E; Csöszi, T; Falcone, A; Fougeray, R; Liposits, G; Martín, L; Moiseenko, F; Polo-Marques, E; Saunders, MP; Shparyk, Y | 1 |
3 trial(s) available for capecitabine and ma-1
| Article | Year |
|---|---|
Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Fluorouracil; Humans; Pyrrolidines; Quality of Life; Thymine; Trifluridine | 2020 |
CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Circulating Tumor DNA; Colonic Neoplasms; Colorectal Neoplasms; Double-Blind Method; Humans; Japan; Neoplasm Recurrence, Local; Oxaliplatin; Prospective Studies; Pyrrolidines; Thymine; Trifluridine | 2021 |
Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Female; Humans; Male; Rectal Neoplasms; Trifluridine | 2023 |
1 other study(ies) available for capecitabine and ma-1
| Article | Year |
|---|---|
Capecitabine induces hand-foot syndrome through elevated thymidine phosphorylase-mediated locoregional toxicity and GSDME-driven pyroptosis that can be relieved by tipiracil.
Topics: Animals; Capecitabine; Deoxycytidine; Fluorouracil; Hand-Foot Syndrome; Mice; Pyroptosis; Quality of Life; Thymidine Phosphorylase | 2023 |